How Esophageal Cancer Is Diagnosed and Staged

Once esophageal cancer is suspected, the workup splits cleanly into two separate jobs: confirming the malignancy, and then staging it, and each uses a different set of tools.

Confirming the Diagnosis

Basic blood work, a complete hemogram, liver function and renal function tests, is done routinely, but the test that actually clinches the diagnosis is endoscopy with biopsy. The endoscopic evaluation serves two purposes: identifying the intraluminal problem causing the swallowing difficulty, and mapping its exact extent from the cricopharynx down to the gastroesophageal junction. The procedure is always coupled with a biopsy of the lesion.

Staging With PET-CT and Endoscopic Ultrasound

Staging investigations follow separately. A CT of the thorax and abdomen is the baseline, though a whole-body PET-CT is now more commonly used, since folding the FDG metabolic study into the CT gives a more accurate stage. A PET scan answers three questions: the tumour's local extent (upper, middle or lower esophagus, and how far around the circumference it spreads), the extent of lymph node involvement across the thoracic, cervical and intra-abdominal regions, and whether there are distant metastases in the lung, liver or peritoneum. In early disease, an endoscopic ultrasound adds more accurate T- and N-staging than PET or CT alone can offer, but if the tumour is tight and strictured, an ultrasound probe may not be able to pass, in which case axial imaging on CT or PET has to carry the staging instead.

When Bronchoscopy and Laparoscopy Are Added

Two further procedures are used selectively rather than routinely. Bronchoscopy is added when imaging shows disease closely abutting the carina or the left main bronchus, when airway invasion is suspected, or when a patient has hoarseness of voice or excessive coughing that raises concern for a tracheo-esophageal fistula; a bronchoscopic EBUS technique can also help stage a strictured tumour that ultrasound cannot reach. Laparoscopy is reserved for adenocarcinoma extending into the gastroesophageal junction and proximal stomach, specifically to rule out omental or peritoneal metastasis before committing to a locally advanced treatment plan.

Staging by TNM

Esophageal cancer is staged using the AJCC TNM system. The esophagus is divided into a cervical segment, extending 15 to 20 cm from the incisors, and a thoracic segment from 20 to 40 cm, itself further divided into upper, middle and lower thirds. T-stage tracks depth of invasion, from disease confined to the mucosa and muscularis mucosa, through the submucosa, into the muscularis reaching the adventitia, and finally into adjacent structures, with resectable structures such as the pleura, pericardium or diaphragm classing as T4a, and unresectable invasion of vital structures like the trachea or aorta classing as T4b. N-stage is a direct node count: one to two nodes is N1, three to six is N2, and seven or more is N3, while disease that spreads beyond the regional nodes to organs such as the liver, lung, or distant nodal stations is classified as metastatic.

Why Getting the Stage Right Matters So Much

Staging isn't just an academic exercise, it decides both the treatment plan and the prognosis. Risk-adjusted survival worsens steadily as stage advances for both adenocarcinoma and squamous cell carcinoma, and at stage two, five-year survival already sits around 30 to 40 percent. An inaccurate stage risks either overtreating an early cancer with unnecessary multimodality therapy, or undertreating a locally advanced one with surgery alone.

This article is based on a Jivo Masterclass session conducted by Dr. Preeti Vijayakumaran, Consultant, Surgical Oncology, Artemis Hospital, Gurugram. The article has been summarised with the assistance of an AI tool from the original masterclass recording. Watch the full Masterclass recording